Corvus touts early data on T cell lymphoma drug, makes PhIII plans
Corvus Pharmaceuticals said that its T cell lymphoma drug helped shrink tumors in patients whose cancer had relapsed, according to an early cut of data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
